Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Dudek
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Dudek

Peter Dudek

Board Member, Mozart Therapeutics

CrunchbaseLinkedIn

Peter Dudek's Career

Mozart Therapeutics
Mozart Therapeutics

Seattle, WA, US

Board Member· Board
Tallac Therapeutics
Tallac Therapeutics

Burlingame, CA, US

Board Member· Board
Ambagon Therapeutics
Ambagon Therapeutics

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Dudek's Career

Mozart Therapeutics
Mozart Therapeutics
Series A$80M312020Seattle, WA, US
Board Member· Board

Leadership at Mozart Therapeutics

Katie FanningKatie FanningCEO
Marie-Claire PeakmanMarie-Claire PeakmanBoard Member
Lucio IannoneLucio IannoneBoard Member
Mark DavisMark DavisFounder

Similar to Mozart Therapeutics

Modulus TherapeuticsModulus TherapeuticsSeattle, WA, USCell Therapies, Therapeuticsest. 2020Modulus TherapeuticsSeattle, WA, US · est. 2020

Modulus: Engineering advanced immune cell therapies for solid tumor treatment.

Seed · $3.5M15
Sonoma BiotherapeuticsSonoma BiotherapeuticsSouth San Francisco, CA, USTreg Therapiesest. 2020Sonoma BiotherapeuticsSouth San Francisco, CA, US · est. 2020

Sonoma Biotherapeutics: Pioneering Treg cell therapies for autoimmune and inflammatory diseases.

Series C · $365M146
Abata TherapeuticsAbata TherapeuticsCambridge, MA, USTreg Therapiesest. 2021Abata TherapeuticsCambridge, MA, US · est. 2021

Abata Therapeutics: Pioneering Treg-engineered therapies for autoimmune diseases.

Series A · $95M57
TregTherapeuticsTregTherapeuticsChapel Hill, NC, USVaccineest. 2018TregTherapeuticsChapel Hill, NC, US · est. 2018

TregTherapeutics, a preclinical-stage company, develops a novel vaccine for multiple sclerosis treatment, leveraging Treg cells' power to alter autoimmune disease outcomes.

Angel · $250k6
Tallac Therapeutics
Tallac Therapeutics
Series A$88.2M342018Burlingame, CA, US
Board Member· Board

Leadership at Tallac Therapeutics

Corey GoodmanCorey GoodmanCo-Founder
Hong I. WanHong I. WanCo-Founder
Ayman KabakibiAyman KabakibiCo-Founder

Similar to Tallac Therapeutics

Tactiva TherapeuticsTactiva TherapeuticsBuffalo, NY, USCancer Treatmentest. 2016Tactiva TherapeuticsBuffalo, NY, US · est. 2016

Tactiva Therapeutics: Specializing in potent dual T cell receptor cancer immunotherapy.

Series A · $35M30
Torl BiotherapeuticsTorl BiotherapeuticsCulver City, CA, USCancer Therapeuticsest. 2018Torl BiotherapeuticsCulver City, CA, US · est. 2018

Culver City-based TORL-Bio, advancing novel antibody-based cancer therapeutics since 2018.

Series B · $158M18
Bolt BiotherapeuticsBolt BiotherapeuticsRedwood City, CA, USCancer Therapeuticsest. 2015Bolt BiotherapeuticsRedwood City, CA, US · est. 2015

Bolt Biotherapeutics: A biotech firm developing immune-stimulating cancer therapeutics, traded publicly in the US.

Public · $198.5M91
LTZ TherapeuticsLTZ TherapeuticsSan Francisco, CA, USImmunotherapy, Therapeuticsest. 2022LTZ TherapeuticsSan Francisco, CA, US · est. 2022

LTZ: Innovating immunotherapies for cancer and diseases with unmet clinical needs.

Seed · $27M16
Ambagon Therapeutics
Ambagon Therapeutics
Series D$148M572020San Francisco, CA, US
Board Member· Board

Leadership at Ambagon Therapeutics

Michelle ArkinMichelle ArkinCo-Founder
Scott ClarkeScott ClarkeCEO
Lucas BrunsveldLucas BrunsveldCo-Founder
Christian OttmannChristian OttmannCo-Founder

Similar to Ambagon Therapeutics

Innovo TherapeuticsInnovo TherapeuticsSan Diego, CA, USAnti-Cancer Drugsest. 2021Innovo TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Innovo Therapeutics develops anti-cancer drugs targeting protein breakdown.

Seed · $200M11
Nexo TherapeuticsNexo TherapeuticsLittleton, CO, USOncology Drugsest. 2022Nexo TherapeuticsLittleton, CO, US · est. 2022

Nexo Therapeutics: Innovating small molecule oncology for effective cancer treatments.

Series A · $60M30
Ensem TherapeuticsEnsem TherapeuticsMedford, MA, USDrug Discoveryest. 2021Ensem TherapeuticsMedford, MA, US · est. 2021

ENSEM Therapeutics: A biotech firm specializing in drug discovery and development for complex oncology targets.

Series A · $77M33
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18

Peter Dudek's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Peter Dudek

Reza HalseReza HalseBoard Member · Spero TherapeuticsPeter DeNagyPeter DeNagyBoard Member · Southern Methodist UniversityMichael MartinMichael MartinBoard Member · OrphoMedDavid CharronDavid CharronBoard Member · PacasoRobert D PrunettiRobert D PrunettiBoard Member · MiaxMike LinnMike LinnBoard Member · Linn Energy